April 2014

Israel's Teva and Japan's Takeda bring parkinson's treatment to Japan. Takeda will develop rasagiline tablets for the Japanese market. Teva Pharmaceutical Industries Ltd. announced that it has signed an agreement with Takeda Pharmaceutical Company Ltd., Japan's largest drug company, allowing Takeda to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline, in Japan. The size of the deal was not disclosed.
 
The annual conference of the CTrials, the Israeli Association for the advancement of the biomedical research community and clinical trials in Israel, was held on April 3rd in The Chaim Sheba Medical Center. The Conference presentations and selected photos can be found here (Hebrew):
 
Hyperion to buy Israeli Andromeda Biotech for up to $570 M. U.S. biopharmaceutical company Hyperion Therapeutics said it agreed to buy Israel's Andromeda Biotech, a developer of a new diabetes drug, in a deal that could be worth close to $600 million. Andromeda is a subsidiary of Clal Biotechnology Industries.
 
61st Annual Conference of the Israel Heart Society. At the end of April, a delegation of ACC faculty led by President Patrick O’Gara, MD, FACC and Past-President, John Harold, MD, MACC has participated in a joint session alongside colleagues from the Israel Heart Society.
 
Intel submits plan for nearly $6 billion Israel chip plant upgrade.  Chip giant Intel Corp submitted a plan to Israel's government to invest 20 billion shekels ($5.8 billion) in upgrading its plant in southern Israel. As part of the investment, Intel would receive a government grant that Israeli media estimated at about 1 billion shekels. They also reported that Intel would add about 1,200 new jobs.